TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02179398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocation to the Lab-score group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allocation to the control group
Study: NCT03928873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy ESWT
Description: 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High energy ESWT
Description: 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ESWT
Description: sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
Study: NCT03803215

Intervention type: DRUG
Intervention: Theophylline
Description: Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
Study: NCT03844438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480226
Description: The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
Study: NCT04837391

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.

Intervention type: DIAGNOSTIC_TEST
Intervention: Addenbrooke Cognitive Examination III (ACE-III)
Description: ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
Study: NCT04169477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFAR Primo Pro (TENS device)
Description: During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFAR Primo Pro (TENS device)
Description: During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.
Study: NCT02615301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with high levels of vitamin D3 and K1
Description: The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with low levels of vitamin D3 and high K1
Description: The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study: NCT02514382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, IV, or IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00747058

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01467258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Single dose
Study: NCT00614198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten- and casein-free diet
Description: Removal of foods containing gluten (cereal produce) and casein (dairy produce)
Study: NCT02514382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study: NCT04047004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Study: NCT00663481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study: NCT03110874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one-way education
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two-way education
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
Study: NCT00474968

Intervention type: DEVICE
Intervention: e2 Cell Collector [SoftPAP(R)]
Description: Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]

Intervention type: DEVICE
Intervention: Spatula/Brush
Description: Cervical cells collected using a combination of a cervical spatula and an endocervical brush
Study: NCT01111292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT01035307

Intervention type: GENETIC
Intervention: gene expression analysis
Study: NCT04047004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Study: NCT00307099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard intravenous antibiotic therapy for a minimum of 8 days.
Study: NCT01035307

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: proteomic profiling

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT00899847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cells (auto-PBSC) transplantation
Description: Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective
Study: NCT02615301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with high levels of vitamin D3 and low K1
Description: The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with vitamin D and Calcium
Description: The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study: NCT02226068

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine A (CsA)
Description: 3 mg/kg/day for 4 month

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine A (CsA)
Description: 3 mg/kg/day for 4 month

Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal photopheresis (ECP)
Description: Administered two consecutive days twice a month for 4 month

Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal photopheresis (ECP)
Description: Administered two consecutive days twice a month for 4 month
Study: NCT00899847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Description: Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection.
Study: NCT00376493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole and doxycycline
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole and doxycycline
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
Study: NCT01521715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
Study: NCT03986801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical interview
Description: pharmaceutical interview at the end of hospitalization
Study: NCT00705003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
Description: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCI-024 (Buspirone)
Description: Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo comparator once a day at bedtime for 6 weeks.
Study: NCT03107091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin acetate continuous infusion
Description: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
Study: NCT00482001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Study: NCT01653951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led care management or peer-led self management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led care management or peer-led self management
Study: NCT03011476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks
Study: NCT04633564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab as MYL-1402O
Description: Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab as Avastin
Description: Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
Study: NCT00909753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Ursodiol Tablets, 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte™
Description: Urso Forte™ Tablets, 500 mg
Study: NCT06558734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
Study: NCT00841698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine HCl
Description: 40 mg Film-Coated Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil®
Description: 40 mg Film-Coated Tablet
Study: NCT04451746

Intervention type: DRUG
Group type: OTHER
Intervention: Combined Oral Contraceptive
Description: The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
Study: NCT00482001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cornstarch)
Study: NCT01788800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 9 sessions of CBT including psychoeducation and interoceptive exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 9 sessions of CBT including psychoeducation and interoceptive exposure
Study: NCT00070148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Megace by mouth for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone 20 mg
Description: 20 mg/day for 3 months (12 weeks)
Study: NCT03969628

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICCMS
Description: Risk caries assessment will consider ICCMS criteria

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICCMS
Description: Risk caries assessment will consider ICCMS criteria
Study: NCT01908556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01744587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate (EGCG)
Description: EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd (2# bid) for 3 years
Study: NCT02030223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: ultrasound guided transversus abdominis plane block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: ultrasound guided transversus abdominis plane block
Study: NCT03199963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-OH tamoxifen
Description: 4-Hydroxytamoxifen (afimoxifene) gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
Study: NCT03260153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deproteinised Calf Blood Serum Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Study: NCT01415986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)
Description: Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
Study: NCT03910231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan, to block V2R

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan, to block V2R

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan, to block V2R
Study: NCT00899847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
Study: NCT03133715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic repair
Description: surgical repair of ventral hernia using laparoscopic repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted repair
Description: surgical repair of ventral hernia using robot-assisted repair
Study: NCT03896425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.